{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:36:44Z","timestamp":1785321404524,"version":"3.55.0"},"reference-count":33,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Traditional Chinese Medicine Science and Technology Plan Project of Zhejiang Province","award":["2023ZF124"],"award-info":[{"award-number":["2023ZF124"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,9,3]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The most common cause of hyperthyroidism, Graves' disease is a common organ-specific autoimmune disease. Selenium is an essential trace element of the human body that is mainly concentrated in the thyroid gland and is involved in the synthesis and metabolism of thyroid hormones. Most studies have shown that the level of selenium is closely related to the occurrence and development of thyroid diseases, and selenium supplementation can help improve thyroid function. This study aims to evaluate the efficacy of selenium supplementation for patients with Graves' hyperthyroidism during methimazole treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>We will search the electronic databases including PubMed, Web of Science, Embase, the Cochrane Library, China National Knowledge Infrastructure, Wanfang Data and Chinese Biomedical Literature, and the time was deadline to December 2023. To evaluate the efficacy of methimazole combined with selenium supplementation in the treatment of Graves' hyperthyroidism, randomised controlled trials will be included. The Cochrane Collaboration\u2019s risk of bias tool will be used to assess the quality of all included studies, and the baseline data of all the studies are extracted by the authors. A random-effects model or a fixed-effects model is used to analyse the outcomes. The primary outcomes are the levels of selenium, triiodothyronine, free thyroxine and thyroid-stimulating hormone (TSH), whereas the secondary outcomes include TSH receptor antibody, thyroid peroxidase antibody and thyroglobulin antibody.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>Ethics approval is not required since no original data will be collected. The results of this study will be published in a peer-reviewed journal.<\/jats:p><\/jats:sec><jats:sec><jats:title>PROSPERO registration number<\/jats:title><jats:p>CRD42023410999<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2023-081302","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T17:50:23Z","timestamp":1727200223000},"page":"e081302","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of selenium supplementation for patients with Graves' hyperthyroidism during methimazole treatment: protocol for a systematic review and meta-analysis"],"prefix":"10.1136","volume":"14","author":[{"given":"Shuo","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9730-1357","authenticated-orcid":false,"given":"Mingxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"2024092410501717000_14.9.e081302.1","first-page":"177","article-title":"Current Diagnosis and Management of Graves\u2019 Disease","volume":"50","author":"Subekti","year":"2018","journal-title":"Acta Med Indones"},{"key":"2024092410501717000_14.9.e081302.2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ecl.2021.12.004","article-title":"2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease","volume":"51","author":"Hoang","year":"2022","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2024092410501717000_14.9.e081302.3","doi-asserted-by":"crossref","first-page":"101387","DOI":"10.1016\/j.beem.2020.101387","article-title":"Graves\u2019 disease: Epidemiology, genetic and environmental risk factors and viruses","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2024092410501717000_14.9.e081302.4","doi-asserted-by":"crossref","first-page":"101388","DOI":"10.1016\/j.beem.2020.101388","article-title":"Graves\u2019 disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Practice & Research Clinical Endocrinology & Metabolism"},{"key":"2024092410501717000_14.9.e081302.5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/cen.14130","article-title":"Diagnostic testing for Graves\u2019 or non-Graves\u2019 hyperthyroidism: A comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography","volume":"92","author":"Scappaticcio","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024092410501717000_14.9.e081302.6","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229"},{"key":"2024092410501717000_14.9.e081302.7","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s11845-018-1939-2","article-title":"Gender impact on the correlations between Graves\u2019 hyperthyroidism and hyperuricemia in Chinese","volume":"188","author":"Liu","year":"2019","journal-title":"Ir J Med Sci"},{"key":"2024092410501717000_14.9.e081302.8","article-title":"Fluctuating Hyperthyroidism and Hypothyroidism in Graves\u2019 Disease: The Swinging Between Two Clinical Entities","volume":"14","author":"Shrestha","year":"2022","journal-title":"Cureus"},{"key":"2024092410501717000_14.9.e081302.9","doi-asserted-by":"crossref","first-page":"651534","DOI":"10.3389\/fendo.2021.651534","article-title":"Hyperthyroidism Prevalence in China After Universal Salt Iodization","volume":"12","author":"Wang","year":"2021","journal-title":"Front Endocrinol"},{"key":"2024092410501717000_14.9.e081302.10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12902-020-00670-w","article-title":"Control of Graves\u2019 hyperthyroidism with very long-term methimazole treatment: a clinical trial","volume":"21","author":"Azizi","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"2024092410501717000_14.9.e081302.11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13256-021-02788-4","article-title":"Efficacy of low-dose methimazole in control of multiple relapses of Graves\u2019 hyperthyroidism: a case report","volume":"15","author":"Azizi","year":"2021","journal-title":"J Med Case Rep"},{"key":"2024092410501717000_14.9.e081302.12","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1089\/thy.2019.0180","article-title":"Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves\u2019 Disease: Results of a Randomized Clinical Trial","volume":"29","author":"Azizi","year":"2019","journal-title":"Thyroid"},{"key":"2024092410501717000_14.9.e081302.13","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.796194","article-title":"The Differential Effects of Propylthiouracil and Methimazole as Graves\u2019 Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial","volume":"12","author":"Wisnu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024092410501717000_14.9.e081302.14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/17446651.2023.2167709","article-title":"Non-thionamide antithyroid drug options in Graves\u2019 hyperthyroidism","volume":"18","author":"Ruslan","year":"2023","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2024092410501717000_14.9.e081302.15","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1097\/IOP.0000000000001136","article-title":"Selenium in Graves Hyperthyroidism and Orbitopathy","volume":"34","author":"Marin\u00f2","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2024092410501717000_14.9.e081302.16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1017\/S0029665118001192","article-title":"Multiple nutritional factors and thyroid disease, with particular reference to autoimmune thyroid disease","volume":"78","author":"Rayman","year":"2019","journal-title":"Proc Nutr Soc"},{"key":"2024092410501717000_14.9.e081302.17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41574-019-0311-6","article-title":"Selenium in thyroid disorders - essential knowledge for clinicians","volume":"16","author":"Winther","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2024092410501717000_14.9.e081302.18","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1210\/jc.2017-01736","article-title":"Randomized Trial of Selenium in Graves Hyperthyroidism","volume":"102","author":"Kahaly","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2024092410501717000_14.9.e081302.19","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.886451","article-title":"Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves\u2019 Disease Hyperthyroidism During Methimazole Treatment","volume":"13","author":"Gallo","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024092410501717000_14.9.e081302.20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40618-016-0559-9","article-title":"Effects of selenium on short-term control of hyperthyroidism due to Graves\u2019 disease treated with methimazole: results of a randomized clinical trial","volume":"40","author":"Leo","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"2024092410501717000_14.9.e081302.21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40618-014-0214-2","article-title":"Role of genetic and non-genetic factors in the etiology of Graves\u2019 disease","volume":"38","author":"Marin\u00f2","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"2024092410501717000_14.9.e081302.22","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41419-023-06041-2","article-title":"Co-inhibition of glutaminolysis and one-carbon metabolism promotes ROS accumulation leading to enhancement of chemotherapeutic efficacy in anaplastic thyroid cancer","volume":"14","author":"Hwang","year":"2023","journal-title":"Cell Death Dis"},{"key":"2024092410501717000_14.9.e081302.23","doi-asserted-by":"crossref","first-page":"154528","DOI":"10.1016\/j.phymed.2022.154528","article-title":"Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway","volume":"108","author":"Hu","year":"2023","journal-title":"Phytomedicine"},{"key":"2024092410501717000_14.9.e081302.24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043418","article-title":"Disulfiram\/Cu Kills and Sensitizes BRAF-Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK\/ERK and PI3K\/AKT Pathways","volume":"24","author":"Xie","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2024092410501717000_14.9.e081302.25","doi-asserted-by":"crossref","unstructured":"Lin X , Xu J , Ma C , et al . Metformin and 2-Deoxy-d-glucose synergistically inhibit the viability of thyroid papillary carcinoma with BRAF mutation by ROS-dependent PI3K\/AKT signaling pathway. Anticancer Agents Med Chem 2023. doi:10.2174\/1871520623666230223124733","DOI":"10.2174\/1871520623666230223124733"},{"key":"2024092410501717000_14.9.e081302.26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11010-022-04541-x","article-title":"ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2\/HO-1 axis","volume":"478","author":"Li","year":"2023","journal-title":"Mol Cell Biochem"},{"key":"2024092410501717000_14.9.e081302.27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s42000-019-00133-5","article-title":"Challenges and perspectives of selenium supplementation in Graves\u2019 disease and orbitopathy","volume":"19","author":"Bednarczuk","year":"2020","journal-title":"Hormones (Athens)"},{"key":"2024092410501717000_14.9.e081302.28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s42000-020-00173-2","article-title":"Selenium involvement in mitochondrial function in thyroid disorders","volume":"19","author":"Gheorghiu","year":"2020","journal-title":"Hormones (Athens)"},{"key":"2024092410501717000_14.9.e081302.29","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1210\/jc.2018-01713","article-title":"Role of Selenium Intake for Risk and Development of Hyperthyroidism","volume":"104","author":"Wang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2024092410501717000_14.9.e081302.30","first-page":"15","article-title":"Role of oxidative stress and selenium in Graves\u2019 hyperthyroidism and orbitopathy","volume":"36","author":"Marcocci","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"2024092410501717000_14.9.e081302.31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3341\/kjo.2021.0146","article-title":"Serum Selenium Levels in Patients with Graves Disease: Associations with Clinical Activity and Severity in a Retrospective Case-control Study","volume":"36","author":"Kim","year":"2022","journal-title":"Korean J Ophthalmol"},{"key":"2024092410501717000_14.9.e081302.32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cccn.2004.08.020","article-title":"Antioxidants and methimazole in the treatment of Graves\u2019 disease: effect on urinary malondialdehyde levels","volume":"352","author":"Guerra","year":"2005","journal-title":"Clin Chim Acta"},{"key":"2024092410501717000_14.9.e081302.33","first-page":"715","article-title":"A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves\u2019 disease","volume":"49","author":"Xu","year":"2019","journal-title":"Turk J Med Sci"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-081302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T17:50:38Z","timestamp":1727200238000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-081302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,24]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/bmjopen-2023-081302"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-081302","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}